




RECEIVED

MAY 31 2001

TECH CENTER 1600/2900



Docket No.: 0585-0017-84

ATTORNEYS AT LAW

ROBERT W. HAHL
(703) 412-6481
RHAHL@OBLON.COM

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

RE: Application Serial No.: 09/226,597
Applicant(s): JULIO PIMENTEL
Filing Date: JANUARY 7, 1999
For: WEIGHT CONTROL USING AN ANTI-LIPASE ANTIBODY
Group No.: 1641
Examiner: GABEL

SIR:

Attached hereto for filing are the following papers:

AMENDMENT

Our check in the amount of \$ -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 CFR 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon
Registration No. 24,618
Attorney of Record

Robert W. Hahl, Ph.D.
Registration No. 33,893



22850



DOCKET NO.: 0585-0017-84

#11/B
6/10/01
Not Entered
entered
6/28/01
gog

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: : GROUP ART UNIT: 1641
JULIO PIMENTEL :
SERIAL NO.: 09/226,597 : EXAMINER: GABEL
FILED: JANUARY 7, 1999 :
FOR: WEIGHT CONTROL USING AN :
ANTI-LIPASE ANTIBODY :

RECEIVED

MAY 31 2001

TECH CENTER 1600/2900

AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

In response to the Official Action dated February 27, 2001, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks.

IN THE CLAIMS

Sub B

I. (Twice Amended) A method for inhibiting the amount of body weight gained after eating, comprising: feeding to an animal an effective amount of a liposome-encapsulated immunoglobulin against lipase.

REMARKS

Claims 1-9 remain active in the application. Undersigned counsel thanks Examiner Gabel for an interview held on March 11, 2001.